Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6433-6441

  Morandi, Fabio ^a   Levreri, Isabella ^a   Bocca, Paola ^a   Galleni, Barbara ^a   Raffaghello, Lizzia ^a   Ferrone, Soldano ^b   Prigione, Ignazia ^a   Pistoia, Vito ^a  

^a G GASLINI INSTITUTE   (Italy)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; HLA G ANTIGEN; INTERLEUKIN 12;

ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CELL LINE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; INCUBATION TIME; MAJOR CLINICAL STUDY; MONOCYTE; NATURAL KILLER T CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN VARIANT; SUPERNATANT; UPREGULATION;

CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; MONOCYTES; NEUROBLASTOMA; NEURONS; RECURRENCE;

EID: 34447118827     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4588     Document Type: Article

References (52)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002;20 Suppl 4:A40-5.
3. Topalian SL, Kasid A, Rosenberg SA. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. J Immunol 1990;144:4487-95.
4. Seung S, Urban JL, Schreiber H. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med 1993;178:933-40.
5. Seliger B, Harders C, Wollscheid U, Staege MS, Reske-Kunz AB, Huber C. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp Hematol 1996;24:1275-9.
6. Rees RC, Mian S. Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol Immunother 1999;48:374-81.
7. Castriconi R, Dondero A, Augugliaro R, et al. Identification of 4Ig-B7-3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A 2004;101:12640-5.
8. Corrias MV, Occhino M, Croce M, et al. Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens 2001;57:110-7.
9. Lampson LA, George DL. Interferon-mediated induction of class I MHC products in human neuronal cell lines: analysis of HLA and h2-mRNA, and HLA-A and HLA-B proteins and polymorphic specificities. J Interferon Res 1986;6:257-65.
10. Raffaghello L, Prigione I, Airoldi I, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett 2005;228:155-61.
11. Raffaghello L, Prigione I, Bocca P, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005;24:4634-44.
12. Shurin GV, Gerein V, Lotze MT, Barksdale EM, Jr. Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand. Nat Immun 1998;16:263-74.
13. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM, Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001;61:363-9.
14. Wolfl M, Batten WY, Posovszky C, Bernhard H, Berthold F. Gangliosides inhibit the development from monocytes to dendritic cells. Clin Exp Immunol 2002;130:441-8.
15. Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 2001;166:5018-26.
16. Marchal-Bras-Goncalves R, Rouas-Freiss N, Connan F, et al. A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc 2001;33:2355-9.
17. Contini P, Ghio M, Poggi A, et al. Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003;33:125-34.
18. Puppo F, Contini P, Ghio M, Indiveri F. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction. Sci World J 2002;2:421-3.
19. Rouas-Freiss N, Kirszenbaum M, Dausset J, Carosella ED. [Fetomaternal tolerance: role of HLA-G molecule in the protection of the fetus against maternal natural killer activity]. C R Acad Sci III 1997;320:385-92.
20. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990;248:220-3.
21. Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997;186:289-98.
22. Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-γ. J Immunol 1996;156:4224-31.
23. Le Friec G, Gros F, Sebti Y, et al. Capacity of myeloid and plasmacytoid dendritic cells especially at mature stage to express and secrete HLA-G molecules. J Leukoc Biol 2004;76:1125-33.
24. Wiendl H, Behrens L, Maier S, Johnson MA, Weiss EH, Hohlfeld R. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol 2000;48:679-84.
25. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002;168:4772-80.
26. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-a immunotherapy. Cancer 2001;92:369-76.
27. Sebti Y, Le Friec G, Pangault C, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003;64:1093-101.
28. Gros F, Sebti Y, de Guibert S, et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 2006;8:223-30.
29. Lefebvre S, Antoine M, Uzan S, et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002;196:266-74.
30. Ibrahim EC, Guerra N, Lacombe MJ, et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 2001;61:6838-45.
31. Urosevic M, Kurrer MO, Kamarashev J, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001;159:817-24.
32. Paul P, Rouas-Freiss N, Khalil-Daher I, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998;95:4510-5.
33. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003;13:371-7.
34. Singer G, Rebmann V, Chen YC, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003;9:4460-4.
35. Rosati R, Torlone N, Papola F, Adorno D, Spagnoli G. [Separation of monocytes and their use in a cytotoxicity test]. Boll Soc Ital Biol Sper 1983;59:1462-6.
36. Fujii T, Ishitani A, Geraghty DE. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol 1994;153:5516-24.
37. van Vreeswijk H, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S. Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. J Invest Dermatol 1988;90:755-60.
38. Tanabe M, Sekimata M, Ferrone S, Takiguchi M. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class Iα3 domain. J Immunol 1992;148:3202-9.
39. Pellegrino MA, Ng AK, Russo C, Glassy M, Ferrone S. Immunochemical analysis of anti-HLA-A2, HLA-A3, and HLA-B27 xenoantisera elicited with hybrids between human and murine cells. Immunogenetics 1981;14:141-52.
40. Indiveri F, Russo C, Quaranta V, Pellegrino MA, Ferrone S. HLA-DR antigens and mitogenic factors released by PWM-stimulated T lymphocytes share the framework determinant recognized by the monoclonal antibody Q5/13. Cell Immunol 1981;62:406-11.
41. Chiesa S, Prigione I, Morandi F, et al. Cytokine flexibility of early and differentiated memory T helper cells in juvenile idiopathic arthritis. J Rheumatol 2004;31:2048-54.
42. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci U S A 1986;83:7893-7.
43. Morandi F, Chiesa S, Bocca P, et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia 2006;8:833-42.
44. Odelstad L, Pahlman S, Lackgren G, Larsson E, Grotte G, Nilsson K. Neuron specific enolase: a marker for differential diagnosis of neuroblastoma and Wilms' tumor. J Pediatr Surg 1982;17:381-5.
45. Berthold F, Hunneman DH, Harms D, Kaser H, Zieschang J. Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma. Eur J Cancer 1992;28A:1950-4.
46. Sanchez-Rovira P, Jimenez E, Carracedo J, Barneto IC, Ramirez R, Aranda E. Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity. Eur J Cancer 1998;34:394-8.
47. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci U S A 1987;84:9145-9.
48. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-63.
49. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2451-61.
50. Rebmann V, Busemann A, Lindemann M, Grosse-Wilde H. Detection of HLA-G5 secreting cells. Hum Immunol 2003;64:1017-24.
51. Natarajan K, Sawicki MW, Margulies DH, Mariuzza RA. Crystal structure of human CD69: a C-type lectinlike activation marker of hematopoietic cells. Biochemistry 2000;39:14779-86.
52. Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cells 1994;12:456-65.